Navigating America’s Prescription Drug Pricing: Over-the-Counter Innovations to Most-Favored-Nation Policies (Part 2)

.

GLP-1s and the Future of Drug Pricing: Novo Nordisk‘s Direct-to-Consumer Move

Health care cost increases forecasted for 2026 will be largely driven by prescription drug trends, especially the rising prices of specialty drugs, specifically GLP-1 medicines and cancer therapies. This week, Novo Nordisk announced a significant move aiming to address affordability concerns: a direct-to-consumer platform offering Ozempic, a popular GLP-1 drug, at a 50% discount – $499 a month – for cash-paying patients. The announcement triggered a 39% rise in goodrx’s stock price, highlighting the market’s reaction to changing dynamics in prescription drug pricing.

This advancement is part of a broader reshaping of the pharmaceutical landscape, as companies seek to address accessibility and affordability. This includes considering a move to a more consumer/patient-driven approach.

With health care costs on the rise, thes changes have implications for individuals navigating the healthcare system, particularly as DRG (diagnosis-Related Group) reforms come into effect, possibly impacting access to optimal treatment and resources.

What role do prescription Assistance Programs (PAPs) play in state-level efforts to improve prescription drug affordability?

The Expanding World of Over-the-counter (OTC) Medications

The shift towards greater access to medications through Over-the-Counter (OTC) options continues to reshape the landscape of prescription drug pricing in the US. This isn’t just about convenience; it’s a significant economic factor.

Recent OTC Switches: Several medications previously requiring a prescription have successfully transitioned to OTC status, including certain allergy medications, migraine relief options, and even birth control pills (Opill, approved in 2023). This increases competition and generally lowers costs for consumers.

Impact on Healthcare Costs: OTC switches reduce the burden on the healthcare system. Fewer doctor visits for refills translate to lower administrative costs and potentially reduced insurance premiums.

Consumer Empowerment: OTC availability empowers individuals to manage their health more proactively, without the necessity of a doctor’s appointment for routine conditions. This is notably relevant for preventative care and managing chronic, stable conditions.

Future OTC candidates: Research is ongoing for potential OTC switches for medications treating conditions like hypertension and type 2 diabetes, promising further cost savings and accessibility.

Understanding the Most Favored nation (MFN) Rule & Its Current Status

The Most Favored Nation (MFN) rule, initially proposed by the Trump management and later revised, aimed to tie Medicare drug prices to those paid in other developed countries.While its implementation faced legal challenges and has been considerably altered,the core concept remains a point of debate.

Original MFN Model: The initial proposal sought to establish a benchmark based on the lowest price paid for certain prescription drugs in a basket of countries.

Legal Challenges & Revisions: Pharmaceutical companies filed lawsuits challenging the rule, arguing it would harm innovation.The Biden administration subsequently revised the rule, narrowing its scope and delaying implementation.

Current Status (August 2025): As of August 2025, the MFN rule is largely inactive. The focus has shifted towards other strategies for drug price negotiation, as outlined in the Inflation Reduction Act.

Potential Future Revivals: The concept of international reference pricing, embodied by the MFN rule, may resurface in future legislative efforts to address high drug costs.

The Inflation Reduction Act: A New Era of Negotiation

The Inflation Reduction Act of 2022 represents the most significant legislative change in decades regarding prescription drug pricing. It allows Medicare to directly negotiate prices for a limited number of high-expenditure drugs.

Negotiation Process: The Centers for Medicare & Medicaid Services (CMS) identifies eligible drugs (those without generic or biosimilar competition) and negotiates prices with manufacturers.

Phased Implementation: Negotiations began in 2023, with the negotiated prices taking effect in 2026. The number of drugs subject to negotiation will increase over time.

Impact on Drug Manufacturers: Manufacturers who refuse to negotiate or fail to reach an agreement face significant excise taxes.

Beneficiary Savings: The Congressional Budget Office (CBO) estimates the Inflation Reduction Act will save Medicare and beneficiaries billions of dollars over the next decade.

Drug Price Transparency: The Act also includes provisions for increased drug price transparency, requiring manufacturers to report certain pricing information to the government.

State-level Initiatives to lower Drug Costs

Beyond federal efforts, numerous states are implementing their own strategies to address prescription drug affordability.

Drug Importation Programs: Several states are exploring or have implemented programs to import prescription drugs from Canada, where prices are often lower. These programs face legal and logistical hurdles.

Price Transparency Laws: Many states have enacted laws requiring drug manufacturers to report pricing information, aiming to shed light on the factors driving high drug costs.

State-Level Negotiation: some states are attempting to negotiate drug prices directly with manufacturers, leveraging their collective purchasing power.

* Prescription Assistance Programs: States are expanding access to prescription assistance programs (PAPs) that help low-income individuals afford their medications.

Navigating Generic and biosimilar Options

Utilizing